Cargando…

Combined miRNA and SERS urine liquid biopsy for the point-of-care diagnosis and molecular stratification of bladder cancer

BACKGROUND: Bladder cancer (BC) has the highest per-patient cost of all cancer types. Hence, we aim to develop a non-invasive, point-of-care tool for the diagnostic and molecular stratification of patients with BC based on combined microRNAs (miRNAs) and surface-enhanced Raman spectroscopy (SERS) pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Moisoiu, Tudor, Dragomir, Mihnea P., Iancu, Stefania D., Schallenberg, Simon, Birolo, Giovanni, Ferrero, Giulio, Burghelea, Dan, Stefancu, Andrei, Cozan, Ramona G., Licarete, Emilia, Allione, Alessandra, Matullo, Giuseppe, Iacob, Gheorghita, Bálint, Zoltán, Badea, Radu I., Naccarati, Alessio, Horst, David, Pardini, Barbara, Leopold, Nicolae, Elec, Florin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8973824/
https://www.ncbi.nlm.nih.gov/pubmed/35365098
http://dx.doi.org/10.1186/s10020-022-00462-z
_version_ 1784680126107090944
author Moisoiu, Tudor
Dragomir, Mihnea P.
Iancu, Stefania D.
Schallenberg, Simon
Birolo, Giovanni
Ferrero, Giulio
Burghelea, Dan
Stefancu, Andrei
Cozan, Ramona G.
Licarete, Emilia
Allione, Alessandra
Matullo, Giuseppe
Iacob, Gheorghita
Bálint, Zoltán
Badea, Radu I.
Naccarati, Alessio
Horst, David
Pardini, Barbara
Leopold, Nicolae
Elec, Florin
author_facet Moisoiu, Tudor
Dragomir, Mihnea P.
Iancu, Stefania D.
Schallenberg, Simon
Birolo, Giovanni
Ferrero, Giulio
Burghelea, Dan
Stefancu, Andrei
Cozan, Ramona G.
Licarete, Emilia
Allione, Alessandra
Matullo, Giuseppe
Iacob, Gheorghita
Bálint, Zoltán
Badea, Radu I.
Naccarati, Alessio
Horst, David
Pardini, Barbara
Leopold, Nicolae
Elec, Florin
author_sort Moisoiu, Tudor
collection PubMed
description BACKGROUND: Bladder cancer (BC) has the highest per-patient cost of all cancer types. Hence, we aim to develop a non-invasive, point-of-care tool for the diagnostic and molecular stratification of patients with BC based on combined microRNAs (miRNAs) and surface-enhanced Raman spectroscopy (SERS) profiling of urine. METHODS: Next-generation sequencing of the whole miRNome and SERS profiling were performed on urine samples collected from 15 patients with BC and 16 control subjects (CTRLs). A retrospective cohort (BC = 66 and CTRL = 50) and RT-qPCR were used to confirm the selected differently expressed miRNAs. Diagnostic accuracy was assessed using machine learning algorithms (logistic regression, naïve Bayes, and random forest), which were trained to discriminate between BC and CTRL, using as input either miRNAs, SERS, or both. The molecular stratification of BC based on miRNA and SERS profiling was performed to discriminate between high-grade and low-grade tumors and between luminal and basal types. RESULTS: Combining SERS data with three differentially expressed miRNAs (miR-34a-5p, miR-205-3p, miR-210-3p) yielded an Area Under the Curve (AUC) of 0.92 ± 0.06 in discriminating between BC and CTRL, an accuracy which was superior either to miRNAs (AUC = 0.84 ± 0.03) or SERS data (AUC = 0.84 ± 0.05) individually. When evaluating the classification accuracy for luminal and basal BC, the combination of miRNAs and SERS profiling averaged an AUC of 0.95 ± 0.03 across the three machine learning algorithms, again better than miRNA (AUC = 0.89 ± 0.04) or SERS (AUC = 0.92 ± 0.05) individually, although SERS alone performed better in terms of classification accuracy. CONCLUSION: miRNA profiling synergizes with SERS profiling for point-of-care diagnostic and molecular stratification of BC. By combining the two liquid biopsy methods, a clinically relevant tool that can aid BC patients is envisaged. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s10020-022-00462-z.
format Online
Article
Text
id pubmed-8973824
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-89738242022-04-02 Combined miRNA and SERS urine liquid biopsy for the point-of-care diagnosis and molecular stratification of bladder cancer Moisoiu, Tudor Dragomir, Mihnea P. Iancu, Stefania D. Schallenberg, Simon Birolo, Giovanni Ferrero, Giulio Burghelea, Dan Stefancu, Andrei Cozan, Ramona G. Licarete, Emilia Allione, Alessandra Matullo, Giuseppe Iacob, Gheorghita Bálint, Zoltán Badea, Radu I. Naccarati, Alessio Horst, David Pardini, Barbara Leopold, Nicolae Elec, Florin Mol Med Research Article BACKGROUND: Bladder cancer (BC) has the highest per-patient cost of all cancer types. Hence, we aim to develop a non-invasive, point-of-care tool for the diagnostic and molecular stratification of patients with BC based on combined microRNAs (miRNAs) and surface-enhanced Raman spectroscopy (SERS) profiling of urine. METHODS: Next-generation sequencing of the whole miRNome and SERS profiling were performed on urine samples collected from 15 patients with BC and 16 control subjects (CTRLs). A retrospective cohort (BC = 66 and CTRL = 50) and RT-qPCR were used to confirm the selected differently expressed miRNAs. Diagnostic accuracy was assessed using machine learning algorithms (logistic regression, naïve Bayes, and random forest), which were trained to discriminate between BC and CTRL, using as input either miRNAs, SERS, or both. The molecular stratification of BC based on miRNA and SERS profiling was performed to discriminate between high-grade and low-grade tumors and between luminal and basal types. RESULTS: Combining SERS data with three differentially expressed miRNAs (miR-34a-5p, miR-205-3p, miR-210-3p) yielded an Area Under the Curve (AUC) of 0.92 ± 0.06 in discriminating between BC and CTRL, an accuracy which was superior either to miRNAs (AUC = 0.84 ± 0.03) or SERS data (AUC = 0.84 ± 0.05) individually. When evaluating the classification accuracy for luminal and basal BC, the combination of miRNAs and SERS profiling averaged an AUC of 0.95 ± 0.03 across the three machine learning algorithms, again better than miRNA (AUC = 0.89 ± 0.04) or SERS (AUC = 0.92 ± 0.05) individually, although SERS alone performed better in terms of classification accuracy. CONCLUSION: miRNA profiling synergizes with SERS profiling for point-of-care diagnostic and molecular stratification of BC. By combining the two liquid biopsy methods, a clinically relevant tool that can aid BC patients is envisaged. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s10020-022-00462-z. BioMed Central 2022-04-01 /pmc/articles/PMC8973824/ /pubmed/35365098 http://dx.doi.org/10.1186/s10020-022-00462-z Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research Article
Moisoiu, Tudor
Dragomir, Mihnea P.
Iancu, Stefania D.
Schallenberg, Simon
Birolo, Giovanni
Ferrero, Giulio
Burghelea, Dan
Stefancu, Andrei
Cozan, Ramona G.
Licarete, Emilia
Allione, Alessandra
Matullo, Giuseppe
Iacob, Gheorghita
Bálint, Zoltán
Badea, Radu I.
Naccarati, Alessio
Horst, David
Pardini, Barbara
Leopold, Nicolae
Elec, Florin
Combined miRNA and SERS urine liquid biopsy for the point-of-care diagnosis and molecular stratification of bladder cancer
title Combined miRNA and SERS urine liquid biopsy for the point-of-care diagnosis and molecular stratification of bladder cancer
title_full Combined miRNA and SERS urine liquid biopsy for the point-of-care diagnosis and molecular stratification of bladder cancer
title_fullStr Combined miRNA and SERS urine liquid biopsy for the point-of-care diagnosis and molecular stratification of bladder cancer
title_full_unstemmed Combined miRNA and SERS urine liquid biopsy for the point-of-care diagnosis and molecular stratification of bladder cancer
title_short Combined miRNA and SERS urine liquid biopsy for the point-of-care diagnosis and molecular stratification of bladder cancer
title_sort combined mirna and sers urine liquid biopsy for the point-of-care diagnosis and molecular stratification of bladder cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8973824/
https://www.ncbi.nlm.nih.gov/pubmed/35365098
http://dx.doi.org/10.1186/s10020-022-00462-z
work_keys_str_mv AT moisoiutudor combinedmirnaandsersurineliquidbiopsyforthepointofcarediagnosisandmolecularstratificationofbladdercancer
AT dragomirmihneap combinedmirnaandsersurineliquidbiopsyforthepointofcarediagnosisandmolecularstratificationofbladdercancer
AT iancustefaniad combinedmirnaandsersurineliquidbiopsyforthepointofcarediagnosisandmolecularstratificationofbladdercancer
AT schallenbergsimon combinedmirnaandsersurineliquidbiopsyforthepointofcarediagnosisandmolecularstratificationofbladdercancer
AT birologiovanni combinedmirnaandsersurineliquidbiopsyforthepointofcarediagnosisandmolecularstratificationofbladdercancer
AT ferrerogiulio combinedmirnaandsersurineliquidbiopsyforthepointofcarediagnosisandmolecularstratificationofbladdercancer
AT burgheleadan combinedmirnaandsersurineliquidbiopsyforthepointofcarediagnosisandmolecularstratificationofbladdercancer
AT stefancuandrei combinedmirnaandsersurineliquidbiopsyforthepointofcarediagnosisandmolecularstratificationofbladdercancer
AT cozanramonag combinedmirnaandsersurineliquidbiopsyforthepointofcarediagnosisandmolecularstratificationofbladdercancer
AT licareteemilia combinedmirnaandsersurineliquidbiopsyforthepointofcarediagnosisandmolecularstratificationofbladdercancer
AT allionealessandra combinedmirnaandsersurineliquidbiopsyforthepointofcarediagnosisandmolecularstratificationofbladdercancer
AT matullogiuseppe combinedmirnaandsersurineliquidbiopsyforthepointofcarediagnosisandmolecularstratificationofbladdercancer
AT iacobgheorghita combinedmirnaandsersurineliquidbiopsyforthepointofcarediagnosisandmolecularstratificationofbladdercancer
AT balintzoltan combinedmirnaandsersurineliquidbiopsyforthepointofcarediagnosisandmolecularstratificationofbladdercancer
AT badearadui combinedmirnaandsersurineliquidbiopsyforthepointofcarediagnosisandmolecularstratificationofbladdercancer
AT naccaratialessio combinedmirnaandsersurineliquidbiopsyforthepointofcarediagnosisandmolecularstratificationofbladdercancer
AT horstdavid combinedmirnaandsersurineliquidbiopsyforthepointofcarediagnosisandmolecularstratificationofbladdercancer
AT pardinibarbara combinedmirnaandsersurineliquidbiopsyforthepointofcarediagnosisandmolecularstratificationofbladdercancer
AT leopoldnicolae combinedmirnaandsersurineliquidbiopsyforthepointofcarediagnosisandmolecularstratificationofbladdercancer
AT elecflorin combinedmirnaandsersurineliquidbiopsyforthepointofcarediagnosisandmolecularstratificationofbladdercancer